Edwards Lifesciences (EW) Stock Price, Fundamentals & Analysis

What EW does

Edwards Lifesciences (EW) develops and sells products and technologies used to treat advanced cardiovascular diseases. Its portfolio includes transcatheter heart valve replacement systems under the Edwards SAPIEN family for minimally invasive aortic valve replacement, as well as transcatheter valve repair and replacement products for mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, including the INSPIRIS and MITRIS RESILIA valves and the KONECT RESILIA tissue valve conduit. Edwards distributes its products through a direct sales force and independent distributors and is part of the S&P 500.

Key numbers explained

• Price and daily change: Edwards Lifesciences trades at 86.82 USD, down 2.21% today.
• Market capitalization: The company's market cap is 49.99 billion USD, reflecting its size in the US stock market.
• Valuation ratios: The trailing P/E ratio is 51.4, while the forward P/E ratio (based on expected earnings) is 25.7. The P/E ratio compares a company's stock price to its earnings per share, helping investors assess relative valuation.
• Earnings per share: Trailing 12-month EPS is 1.69 USD.
• Dividend: The dividend yield is 0%, and 0% of earnings are paid out as dividends.
• Risk metric: The beta is 0.85, indicating lower volatility than the broader market.
• Price range: The 52-week low and high are 72.3 USD and 96.29 USD, respectively. Over the last 52 weeks, the stock has risen 18.9%.
• Revenue: Trailing 12-month revenue is 6.51 billion USD, with a year-over-year growth of 13.6%.
• Profitability: The profit margin is 15.4%, and the operating margin is 29.8%.
• Return on equity: 9.2%.
• Leverage: The debt-to-equity ratio is 6.6%.
• Price-to-book: 4.71.
• Next earnings date: **29 Oct. 2